vimarsana.com

New Delhi [India], August 27 (ANI/PNN): Advanced genetic sequencing for cancer patients would now become more affordable and easily accessible with the newly announced collaboration between GenepoweRx, India's most trusted Genetic Testing company, and Onco.com, India's leading patient-centric cancer care management platform. These two well-known names in their industries have agreed to work together in carrying out advanced cancer genomics tests and reporting accurate recommendations specific to the Indian population towards targeted therapy in cancer. As per WHO 2020 report, 1 in 10 Indians will develop cancer in their lifetime, and 1 in 15 will die of the disease. Average survival after the diagnosis improved significantly after the advent of targeted therapies. Targeted therapy is an advanced and new form of cancer treatment which focuses on the root causes, i.e. genetic changes or mutations that turn healthy cells into cancer cells. There are over 82 FDA-approved targeted therapy drugs covering more than 15 types of cancers, including those of the breast, prostate, colon, and lung; these targeted therapies work precisely if the tumour has the right target. To use targeted therapy, the oncologist recommends genetic tests to understand the genetic changes responsible for cancer cell growth. With the growing incidents of cancer in India and the rising need for oncogene-specific genetic testing specific to the Indian population, this collaboration is a much-needed hope for cancer patients. Onco.com is India's leading patient-centric cancer care management platform offering end-to-end support to cancer patients and their families. It has a PAN-India presence with over 1500 oncologists and more than 500 treatment centres consisting of hospitals, clinics, and Onco cancer centres. GenepoweRx, is India's most trusted Genetic Testing company founded by Dr. Kalyan and Dr. Hima, both American Board-certified Internal Medicine Physicians with over 10 years of training and experience in clinical genomics from prestigious Stanford and Harvard University. The company takes pride in developing India's first comprehensive Cancer Genetic Test - OncoRx, which will help oncologists to prescribe targeted therapy drugs. OncoRx is the only genetic test powered by Artificial Intelligence(AI) algorithms using US basedMemorial Sloan Kettering Cancer Center'sPrecision Oncology Knowledge Base, the only FDA-recognized database for cancer to identify gene mutations associated with solid tumors and to provide accurate recommendations specific to the Indian population. There are significant variations in the cancer genome changes between different ethnicities. Recently, the data analysis from the world's oldest and only FDA-approved database from Memorial Sloan Kettering cancer centre revealed that EGFR mutations are more common in Asians (56 per cent) when compared with Caucasians (16 per cent). GenepoweRx bio-medical-informatics team has sequenced over 100 solid tumor samples in recent months and found that there are mutations which have specific therapies and facilitated the provision of specific medications on compassionate grounds from international drug manufacturers. Many novel mutations found in our population have not been reported so far in the global database. GenepoweRx is currently working on publishing these findings and deciphering the clinical importance. Dr Kalyan, Founder - GenepoweRx shares, "We are proud to collaborate with Onco.com. More sequencing of tumor cells is needed. We carry a mutual goal of bringing world-class advanced testing to all our patients at an affordable cost. This partnership will provide more insights into the reasons for the rise in cancer and possibly identify new targeted therapies. Collaborations like these will help provide better cancer treatment options to the masses." Dr Amit Jotwani, Co-founder and Chief Oncologist, says, "I believe collaboration is the way forward to bring meaningful advancements in the fight against cancer. Cancer Genomics testing is gaining tremendous interest due to its ability to identify the most effective targeted treatments, but at the same time, the test outcomes may not give clear results due to the complexity of different mutations that may be found. Additionally, a limited understanding of mutation patterns in Indian patients makes it difficult to develop targeted therapies. Collaboration with GenepoweRx's AI-based platform will help us better understand cancer-causing mutations among the Indian population, which in turn would help us develop more effective and affordable drugs". In the era of personalized medicine, genomic testing is an indispensable tool. It will lead to informed decisions and better patient outcomes with reduced side effects. This Story has been provided by PNN. ANI will not be responsible in any way for the content in this article. (ANI/PNN)

Related Keywords

India ,United States ,Kalyan ,Maharashtra ,New Delhi ,Delhi ,American ,Sloan Kettering ,Amit Jotwani ,Harvard University ,Genetic Testing ,Cancer Genetic Test ,Artificial Intelligence ,Memorial Sloan Kettering ,Chief Oncologist ,New Delhi India ,Ugust 27 Ani Pnn Advanced Genetic Sequencing For Cancer Patients Would Now Become More Affordable And Easily Accessible With The Newly Announced Collaboration Between Genepowerx ,Ndia 39s Most Trusted Genetic Testing Company ,Nd Onco Com ,Ndia 39s Leading Patient Centric Cancer Care Management Platform These Two Well Known Names In Their Industries Have Agreed To Work Together Carrying Out Advanced Genomics Tests And Reporting Accurate Recommendations Specific The Indian Population Towards Targeted Therapy As Per Who 2020 Report , In 10 Indians Will Develop Cancer Their Lifetime ,Nd 1 In 15 Will Die Of The Disease Average Survival After Diagnosis Improved Significantly Advent Targeted Therapies Therapy Is An Advanced And New Form Cancer Treatment Which Focuses On Root Causes ,E Genetic Changes Or Mutations That Turn Healthy Cells Into Cancer There Are Over 82 Fda Approved Targeted Therapy Drugs Covering More Than 15 Types Of Cancers ,Ncluding Those Of The Breast ,Prostate ,Colon ,Nd Lung These Targeted Therapies Work Precisely If The Tumour Has Right Target To Use Therapy ,He Oncologist Recommends Genetic Tests To Understand The Changes Responsible For Cancer Cell Growth With Growing Incidents Of In India And Rising Need Oncogene Specific Testing Indian Population ,His Collaboration Isa Much Needed Hope For Cancer Patients Onco Com Is India 39s Leading Patient Centric Care Management Platform Offering End To Support And Their Families It Hasa Pan Presence With Over 1500 Oncologists More Than 500 Treatment Centres Consisting Of Hospitals ,Clinics ,Nd Onco Cancer Centres Genepowerx ,S India 39s Most Trusted Genetic Testing Company Founded By Dr Kalyan And Hima ,Oth American Board Certified Internal Medicine Physicians With Over 10 Years Of Training And Experience In Clinical Genomics From Prestigious Stanford Harvard University The Company Takes Pride Developing India 39s First Comprehensive Cancer Genetic Test Oncorx ,Hich Will Help Oncologists To Prescribe Targeted Therapy Drugs Oncorx Is The Only Genetic Test Powered By Artificial Intelligence Ai Algorithms Using Us Basedmemorial Sloan Kettering Cancer Center 39 Sprecision Oncology Knowledge Base ,He Only Fda Recognized Database For Cancer To Identify Gene Mutations Associated With Solid Tumors And Provide Accurate Recommendations Specific The Indian Population There Are Significant Variations In Genome Changes Between Different Ethnicities Recently ,He Data Analysis From The World 39s Oldest And Only Fda Approved Database Memorial Sloan Kettering Cancer Centre Revealed That Egfr Mutations Are More Common In Asians 56 Per Cent When Compared With Caucasians 16 Genepowerx Bio Medical Informatics Team Has Sequenced Over 100 Solid Tumor Samples Recent Months Found There Which Have Specific Therapies Facilitated Provision Of Medications On Compassionate Grounds International Drug Manufacturers Many Novel Our Population Not Been Reported So Far Global Is Currently Working Publishing These Findings Deciphering Clinical Importance Dr Kalyan ,Ounder Genepowerx Shares ,Uot We Are Proud To Collaborate With Onco Com More Sequencing Of Tumor Cells Is Needed Carrya Mutual Goal Bringing World Class Advanced Testing All Our Patients At An Affordable Cost This Partnership Will Provide Insights Into The Reasons For Rise In Cancer And Possibly Identify New Targeted Therapies Collaborations Like These Help Better Treatment Options Masses Quot Dr Amit Jotwani ,O Founder And Chief Oncologist ,Ways ,Uoti Believe Collaboration Is The Way Forward To Bring Meaningful Advancements In Fight Against Cancer Genomics Testing Gaining Tremendous Interest Due Its Ability Identify Most Effective Targeted Treatments ,Out At The Same Time ,He Test Outcomes May Not Give Clear Results Due To The Complexity Of Different Mutations That Be Found Additionally ,A Limited Understanding Of Mutation Patterns In Indian Patients Makes It Difficult To Develop Targeted Therapies Collaboration With Genepowerx 39s Ai Based Platform Will Help Us Better Understand Cancer Causing Mutations Among The Population ,Hich In Turn Would Help Us Develop More Effective And Affordable Drugs Quot The Era Of Personalized Medicine ,Enomic Testing Is An Indispensable Tool It Will Lead To Informed Decisions And Better Patient Outcomes With Reduced Side Effects This Story Has Been Provided By Pnn Ani Not Be Responsible In Any Way For The Content Article ,

© 2025 Vimarsana

vimarsana.com © 2020. All Rights Reserved.